Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRD.

A.H. Young, L. Bartova, N. Cardoner, K. Demyttenaere, A. Fagiolini, Y. Godinov, J.F. Golib Dzib, C. Von Holt, R.S. McIntyre, A.J. Oliveira-Maia, B. Rive, P. Gorwood

Eur Psychiatry June 16, 2026 DOI: 10.1192/j.eurpsy.2026.12229 (opens in new tab) via PubMed

Relevant Not relevant

Study at a glance

Characteristics	Peer reviewed

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry European Psychiatry June 23, 2026 via OpenAlex
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study". Eur Neuropsychopharmacol June 5, 2026 via PubMed
Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. International journal of psychiatry in clinical practice June 1, 2024 3 citations via PubMed
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2026 3 citations via PubMed
Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes. Journal of psychopharmacology (Oxford, England) March 21, 2026 via PubMed

Comments

No comments yet.

Study at a glance

Abstract

Related reading

Comments